hemay022 + letrozole

Hemay022 + letrozole is an investigational combination therapy currently being assessed in phase III clinical trials for the treatment of estrogen receptor-positive (ER+)/HER2-positive advanced or metastatic breast cancer in postmenopausal women who have experienced prior treatment failure with trastuzumab regimens[1][3][6]. Hemay022 is a novel, small-molecule irreversible tyrosine kinase inhibitor that targets both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), effectively inhibiting the proliferation of HER2-overexpressing tumor cells by blocking downstream signaling[5]. Letrozole is a well-established, non-steroidal aromatase inhibitor that suppresses estrogen biosynthesis, thereby restricting hormone-dependent tumor growth. The combination leverages dual blockade of HER2 and estrogen signaling pathways for improved anti-tumor efficacy in a population with limited treatment options[1][3][6].

Other names

hemay022 + letrozole